CClinicalTrials.gg
Sign In
Not yet recruitingNCT07790276GLANCE-PDUpdated Aug 27, 2026

Continuous Glucose Monitoring and Clinical Outcomes in Diabetes on Peritoneal Dialysis

An observational study in Continuous Glucose Monitoring, ESRD (End-Stage Renal Disease) and Peritoneal Dialysis (PD), sponsored by Elaine Chow. Not yet recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Elaine Chow · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This prospective, multicenter observational study will evaluate glucose profiles using continuous glucose monitoring (CGM) in 100 adults with diabetes receiving peritoneal dialysis (PD) or planning to start PD within 3 months. The study will examine associations between CGM metrics and PD regimen, glucose-lowering treatment, conventional glycemic markers, dialysis-related measures, and clinical outcomes including glycemic emergencies, hospitalizations, cardiovascular events, and mortality over 12 months.

02

Conditions studied

  • Continuous Glucose Monitoring
  • ESRD (End-Stage Renal Disease)
  • Peritoneal Dialysis (PD)
  • Diabetes Mellitus (DM)
03

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with diabetes and stage 5 chronic kidney disease who are receiving peritoneal dialysis or are planned to initiate peritoneal dialysis within 3 months.

Inclusion criteria

  1. Stage 5 CKD patients

    1. who have received PD for at least 3 months, OR
    2. who are planned for PD within the next 3 months.
  2. Age 18-80 years old
  3. Known history of type 1 or type 2 diabetes for at least 3 months
  4. Women who are not pregnant, lactating or planning a pregnancy during their participation in the clinical study.
  5. Willingness, ability and commitment to comply with the testing, procedure and follow-up outlined in this protocol including (but not limited to) frequency of clinic visits and use of pre-specified glucose monitoring devices.
  6. Willingness to abstain from swimming during their participation in the measurement phase.
  7. In the opinion of the investigator, absence of any physical limitations, addictive diseases, or underlying medical conditions (including mental health) that may preclude the patient from being a good study candidate.
  8. Written informed consent to participate in the study provided by the patient.

Exclusion criteria

Exclusion criteria:

  1. Patients who are planning to switch to hemodialysis or renal transplant in the coming 3 months
  2. Life expectancy \<6 months
  3. Extensive skin changes/diseases that preclude wearing the required number of devices on normal skin at the proposed application sites
  4. HbA1c > 11% at enrolment
  5. Currently pregnant, as demonstrated by a positive pregnancy test at screening for women of reproductive potential.
  6. Any active acute or chronic disease or condition that, in the opinion of the investigator, might interfere with the performance of this study.
  7. Any active acute or chronic infectious disease that, in the opinion of the investigator, would pose an excessive risk to study staff.
  8. Current use or recent exposure to any medication that in the opinion of the investigator could have an influence on the patient's ability to participate in this study or on the performance of the test device.
  9. Have a known allergy to medical-grade adhesives or known hypersensitivity to any of the products used in the study.
  10. Have MRI scan, CT scan, or diathermy scheduled during the proposed period of sensor wearing during the study
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Groups and cohorts

  • peritoneal dialysis group

    Adults with diabetes and stage 5 chronic kidney disease who have been receiving peritoneal dialysis for at least 3 months at enrollment.

    Device: Continuous glucose monitoring system

  • pre-peritoneal dialysis group

    Adults with diabetes and stage 5 chronic kidney disease who are planned to initiate peritoneal dialysis within 3 months after enrollment.

    Device: Continuous glucose monitoring system

Interventions

  • DeviceContinuous glucose monitoring system

    Sibionics GS3 CGM

05

What researchers measure

Primary outcomes

  1. Continuous glucose monitoring-derived metrics

    CGM derived time in ranges

    Time frame: During period of 14 day CGM wear

Secondary outcomes

  1. HbA1c

    HbA1c by venous blood

    Time frame: Baseline to end of study period month 12

  2. 24-hour dialysate and ultrafiltration volume

    24-hour dialysate and ultrafiltration volume,

    Time frame: Baseline through to month 12

  3. Residual renal function

    Defined by 24-hour urine volume

    Time frame: From baseline through 12 months

  4. Hospitalization for hyperglycemic or hypoglycemic emergencies

    Incidence of hospitalization due to hyperglycemic or hypoglycemic emergencies during follow-up

    Time frame: From baseline through 12 months

  5. Hospitalizations, cardiovascular events, and all-cause mortality

    Incidence of all-cause hospitalization, major cardiovascular events, and all-cause mortality during follow-up

    Time frame: From baseline through 12 months

  6. Dietary intake during CGM wear

    Dietary intake assessed using a 3-day food diary

    Time frame: During the 14-day CGM wear period

  7. Health-related quality of life

    EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) overall score

    Time frame: Baseline

  8. Quality of life specific to kidney disease

    Kidney Disease Quality of Life-36 questionnaire (KDQOL-36) total score

    Time frame: Baseline

  9. CGM user satisfaction

    Total score from 10-item CGM user satisfaction questionnaire

    Time frame: Baseline and month 3

06

Study locations

1 site
  • Department of Medicine and Therapeutics, The Chinese University of Hong Kong
    Hong Kong, Hong Kong
    • Elaine Chow · Contact · e.chow@cuhk.edu.hk · +85235051549
    • Jack Kit Chung Ng · Sub investigator
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07790276
Lead sponsor
Elaine Chow
Responsible party
Elaine Chow (Clinical Associate Professor, Chinese University of Hong Kong) — Sponsor-investigator
First posted
Aug 27, 2026
Start date
Aug 31, 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Elaine Chow
Contact
e.chow@cuhk.edu.hk
+85235051549
Elaine Chow
principal investigator · Department of Medicine and Therapeutics, The Chinese University of Hong Kong

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Renal Insufficiency, Chronic→

Other studies from this sponsor

Elaine Chow

Start the discussion